

Anette E Schrag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120106/publications.pdf>

Version: 2024-02-01

274
papers

28,954
citations

7096

78
h-index

5829

161
g-index

294
all docs

294
docs citations

294
times ranked

20082
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 1-12.	4.7	12
2	Clinical precursors of tics: an EMTICS study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 305-314.	5.2	15
3	Rate of Hospitalizations and Underlying Reasons Among People with Parkinson's Disease: Population-Based Cohort Study in UK Primary Care. <i>Journal of Parkinson's Disease</i> , 2022, 12, 411-420.	2.8	8
4	Identification of Prodromal Presentations of Parkinson's Disease among Primary Care Outpatients in Germany. <i>Neuroepidemiology</i> , 2022, 56, 41-49.	2.3	6
5	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , The, 2022, 21, 89-102.	10.2	142
6	Systematic review and meta-analysis of clinical effectiveness of self-management interventions in Parkinson's disease. <i>BMC Geriatrics</i> , 2022, 22, 45.	2.7	18
7	Caregiver Burden and Quality of Life in Late Stage Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 111.	2.3	13
8	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinson's disease: a Distal Finger Tapping test. <i>Scientific Reports</i> , 2022, 12, 386.	3.3	22
9	Change in the incidence of Parkinson's disease in a large UK primary care database. <i>Npj Parkinson's Disease</i> , 2022, 8, 23.	5.3	12
10	Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 101-104.	2.2	10
11	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	9.0	25
12	The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England. <i>Pharmacoeconomics</i> , 2022, 40, 559-574.	3.3	5
13	Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 639-654.	2.3	7
14	Confidence College – an online education tool for neurology patients. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2022, 21, 6-9.	0.1	0
15	Exploring the experiences of people and family carers from under-represented groups in self-managing Parkinson's disease and their use of digital health to do this. <i>Digital Health</i> , 2022, 8, 205520762211022.	1.8	4
16	Lower lymphocyte count is associated with increased risk of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A94.3-A95.	1.9	0
17	249... Slow motion analysis of repetitive tapping (SMART) test: a new measurement of bradykinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A85.2-A85.	1.9	0
18	Parkinson's disease determinants, prediction and gene-environment interactions: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A7.3-A8.	1.9	0

#	ARTICLE	IF	CITATIONS
19	228â€¦ Testing shortened versions of smell tests to screen for hyposmia in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A79.2-A79.	1.9	0
20	Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinson's Disease, 2022, 2022, 1-7.	1.1	4
21	The effectiveness of aromatherapy and reflexology in neurodegenerative disorders: a systematic review and meta-analysis. Neurodegenerative Disease Management, 2022, 12, 253-265.	2.2	1
22	Transitions and challenges for people with Parkinsonâ€™s and their family members: A qualitative study. PLoS ONE, 2022, 17, e0268588.	2.5	4
23	Characterization of Nonâ€Motor Fluctuations Using the Movement Disorder Society <scp>Nonâ€Motor</scp> Rating Scale. Movement Disorders Clinical Practice, 2022, 9, 932-940.	1.5	5
24	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Movement Disorders, 2021, 36, 283-297.	3.9	52
25	Prevalence of Nonâ€Motor Symptoms and Nonâ€Motor Fluctuations in Parkinson's Disease Using the <scp>MDSâ€NMS</scp>. Movement Disorders Clinical Practice, 2021, 8, 231-239.	1.5	35
26	Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinsonâ€™s disease: a cross-sectional study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 158-164.	1.9	29
27	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinsonâ€™s Disease Living in the United Kingdom. Journal of Parkinson's Disease, 2021, 11, 299-307.	2.8	15
28	Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. Journal of the American Medical Directors Association, 2021, 22, 440-445.e2.	2.5	18
29	The Nonâ€Motor Symptoms Scale in Parkinsonâ€™s disease: Validation and use. Acta Neurologica Scandinavica, 2021, 143, 3-12.	2.1	49
30	The motor prodromes of parkinsonâ€™s disease: from bedside observation to large-scale application. Journal of Neurology, 2021, 268, 2099-2108.	3.6	27
31	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
32	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. Neurology, 2021, 96, e1680-e1693.	1.1	30
33	Sequence of clinical and neurodegeneration events in Parkinsonâ€™s disease progression. Brain, 2021, 144, 975-988.	7.6	49
34	Resource Utilization of Patients with Parkinsonâ€™s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study. Pharmacoeconomics, 2021, 39, 601-615.	3.3	11
35	Perspectives on Care for Late-Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2021, 2021, 1-11.	1.1	13
36	Factors Associated with Healthâ€Related Quality of Life in Lateâ€Stage Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 563-570.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	5.3	13
38	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1901-1915.	2.8	6
39	Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration. <i>Movement Disorders</i> , 2021, 36, 2811-2820.	3.9	8
40	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 186-194.	2.2	26
41	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers—Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 673893.	2.4	7
42	Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations. <i>Movement Disorders</i> , 2021, 36, 2481-2493.	3.9	15
43	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	5.3	4
44	<i>Mycoplasma pneumoniae</i> IgG positivity is associated with tic severity in chronic tic disorders. <i>Brain, Behavior, and Immunity</i> , 2021, 99, 281-288.	4.1	6
45	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	3.3	11
46	Health care professionals' perspectives on self-management for people with Parkinson's: qualitative findings from a UK study. <i>BMC Geriatrics</i> , 2021, 21, 706.	2.7	14
47	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	3.9	59
48	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	1.9	59
49	Self-Management Components as Experienced by People with Parkinson's Disease and Their Carers: A Systematic Review and Synthesis of the Qualitative Literature. <i>Parkinson's Disease</i> , 2020, 2020, 1-10.	1.1	18
50	What contributes to quality of life in Parkinson's disease: a re-evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 563-565.	1.9	6
51	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020, 35, 1658-1662.	3.9	11
52	Factor Analysis and Clustering of the Movement Disorder Society's "Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020, 35, 969-975.	3.9	9
53	Experiences of advance care planning in Parkinson's disease and atypical parkinsonian disorders: a mixed methods systematic review. <i>European Journal of Neurology</i> , 2020, 27, 1971-1987.	3.3	16
54	Anti-dopamine D2 receptor antibodies in chronic tic disorders. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1205-1212.	2.1	15

#	ARTICLE	IF	CITATIONS
55	Brain iron deposition is linked with cognitive severity in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 418-425.	1.9	121
56	Factors associated with hospitalisation among people with Parkinson's disease – A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 66-72.	2.2	51
57	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020, 27, 944-950.	3.3	15
58	The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 531-542.	1.5	24
59	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 394-398.	1.5	11
60	Visual tests predict dementia risk in Parkinson disease. <i>Neurology: Clinical Practice</i> , 2020, 10, 29-39.	1.6	41
61	The late stage of Parkinson's – results of a large multinational study on motor and non-motor complications. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 91-96.	2.2	25
62	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	4.7	36
63	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 665-669.	4.1	15
64	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	7.6	90
65	Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-U-MRS). <i>Movement Disorders Clinical Practice</i> , 2019, 6, 227-234.	1.5	31
66	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49
67	Neuropsychiatric aspects of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 889-896.	2.8	25
68	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	5.3	26
69	Screening performance of abbreviated versions of the UPSIT smell test. <i>Journal of Neurology</i> , 2019, 266, 1897-1906.	3.6	37
70	Heterogeneity in progression of prodromal features in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 275-279.	2.2	15
71	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2019, 126, 925-932.	2.8	11
72	Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations. <i>Movement Disorders</i> , 2019, 34, 480-486.	3.9	69

#	ARTICLE	IF	CITATIONS
73	Experiences of health services and unmet care needs of people with late-stage Parkinson's in England: A qualitative study. PLoS ONE, 2019, 14, e0226916.	2.5	26
74	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 30.	5.3	32
75	The prodromes of Parkinson's disease. European Journal of Neuroscience, 2019, 49, 320-327.	2.6	30
76	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
77	Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK. Movement Disorders, 2018, 33, 974-981.	3.9	53
78	Dopamine reuptake transporter single-photon emission computed tomography and transcranial sonography as imaging markers of pre-diagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
79	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 479-491.	1.5	18
80	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism and Related Disorders, 2018, 52, 83-89.	2.2	46
81	Patient experiences of receiving a diagnosis of Parkinson's disease. Journal of Neurology, 2018, 265, 1151-1157.	3.6	21
82	Mild Cognitive Impairment in Parkinson's Disease: What Is It?. Current Neurology and Neuroscience Reports, 2018, 18, 17.	4.2	57
83	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. Parkinson's Disease, 2018, 2018, 1-9.	1.1	4
84	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology, 2018, 18, 185.	1.8	27
85	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. BJPsych Open, 2018, 4, 404-410.	0.7	3
86	An early diagnosis is not the same as a timely diagnosis of Parkinson's disease. F1000Research, 2018, 7, 1106.	1.6	30
87	Testing the MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1518-1520.	3.9	4
88	Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association. European Journal of Neurology, 2018, 25, 1410.	3.3	21
89	Can neuroimaging predict dementia in Parkinson's disease?. Brain, 2018, 141, 2545-2560.	7.6	46
90	The subjective experience of Parkinson's disease: A qualitative study in 60 people with mild to moderate Parkinson's in 11 European countries. European Journal for Person Centered Healthcare, 2018, 6, 447.	0.3	6

#	ARTICLE	IF	CITATIONS
91	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	3.9	59
92	Differences in <scp>MDS</scp>â€<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	1.5	65
93	Rasch analysis of the carers quality of life questionnaire for parkinsonism. <i>Movement Disorders</i> , 2017, 32, 463-466.	3.9	3
94	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	1.9	19
95	Cognitive decline before diagnosis of Parkinson's disease â€“ Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 262.	10.2	2
96	Viral hepatitis and Parkinson disease. <i>Neurology</i> , 2017, 88, 1630-1633.	1.1	47
97	The Catsâ€andâ€Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1789-1790.	3.9	26
98	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. <i>Neuroepidemiology</i> , 2017, 49, 1-17.	2.3	29
99	Reply: MRI findings of visual system alterations in Parkinsonâ€™s disease. <i>Brain</i> , 2017, 140, e70-e70.	7.6	0
100	Depression and Anxiety in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 623-655.	2.0	107
101	Study protocol: Insight 46 â€“ a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurology</i> , 2017, 17, 75.	1.8	64
102	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 66-75.	10.2	304
103	Current concepts and controversies in the pathogenesis of Parkinsonâ€™s disease dementia and Dementia with Lewy Bodies. <i>F1000Research</i> , 2017, 6, 1604.	1.6	35
104	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. <i>PLoS Medicine</i> , 2017, 14, e1002314.	8.4	152
105	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders</i> , 2016, 31, 1455-1465.	3.9	87
106	Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1342-1355.	3.9	212
107	Healthcare Resource Utilisation And Cost Of Parkinsonâ€™s Disease In The United Kingdom. <i>Value in Health</i> , 2016, 19, A428-A429.	0.3	1
108	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 527-537.	1.5	46

#	ARTICLE	IF	CITATIONS
109	Serotonergic loss underlying apathy in Parkinson's disease. <i>Brain</i> , 2016, 139, 2338-2339.	7.6	9
110	Visual dysfunction in Parkinson's disease. <i>Brain</i> , 2016, 139, 2827-2843.	7.6	320
111	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	3.9	55
112	Challenges of modifying disease progression in prediagnostic Parkinson's disease. <i>Lancet Neurology</i> , 2016, 15, 637-648.	10.2	78
113	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016, 25, 81-88.	3.1	20
114	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 710-716.	1.9	152
115	New clinical trials for nonmotor manifestations of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1490-1504.	3.9	81
116	Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls. <i>Npj Parkinson's Disease</i> , 2015, 1, 15011.	5.3	44
117	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. <i>Movement Disorders</i> , 2015, 30, 1002-1003.	3.9	6
118	A new scale for the assessment of pain in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1589-1590.	3.9	0
119	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 127-134.	1.5	20
120	CONSTIPATION PRECEDING PARKINSON'S DISEASE—META-ANALYSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.193-e4.	1.9	5
121	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. <i>Lancet Neurology</i> , 2015, 14, 57-64.	10.2	487
122	Psychosis in Parkinson's Disease. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , 113-139.	0.3	1
123	Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study. <i>Quality of Life Research</i> , 2015, 24, 1899-1910.	3.1	2
124	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	1.9	90
125	Genetic comorbidities in Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 831-841.	2.9	57
126	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 169-176.	3.9	15

#	ARTICLE	IF	CITATIONS
127	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	2.6	25
128	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 317-324.	1.5	32
129	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	2.6	47
130	Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 35.	2.4	18
131	Dystonia rating scales: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 874-883.	3.9	150
132	Time trends in incidence of Parkinson's disease diagnosis in UK primary care. <i>Journal of Neurology</i> , 2013, 260, 1351-1357.	3.6	49
133	Olfactory impairment and pathology in neurodegenerative disorders with brain iron accumulation. <i>Acta Neuropathologica</i> , 2013, 126, 151-153.	7.7	9
134	Imaging Psychogenic Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 402.	4.2	15
135	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013, 12, 264-274.	10.2	426
136	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 1793-1800.	3.9	124
137	EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	3.3	460
138	Coactivation sign in fixed dystonia. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 474-476.	2.2	8
139	Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). <i>Revue Neurologique</i> , 2013, 169, 53-58.	1.5	5
140	The functional neuroimaging correlates of psychogenic versus organic dystonia. <i>Brain</i> , 2013, 136, 770-781.	7.6	83
141	Health-Related Quality of Life in Gilles de la Tourette Syndrome: A Decade of Research. <i>Behavioural Neurology</i> , 2013, 27, 83-93.	2.1	85
142	Health-related quality of life in Gilles de la Tourette syndrome: a decade of research. <i>Behavioural Neurology</i> , 2013, 27, 83-93.	2.1	49
143	What is the clinically relevant change on the ADAS-cog?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, e1.187-e1.	1.9	82
144	What is the clinically relevant change on the ADAS-Cog?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 171-173.	1.9	117

#	ARTICLE	IF	CITATIONS
145	Kayserâ€Fleischer Rings in Wilson's Disease. New England Journal of Medicine, 2012, 366, e18.	27.0	4
146	Scales to detect depression in Parkinson disease. Nature Reviews Neurology, 2012, 8, 359-360.	10.1	9
147	120â€An algorithm to identify individuals at high-risk of Parkinson's disease in the community. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.71-e1.	1.9	0
148	119â€A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.70-e1.	1.9	0
149	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
150	Levodopa-Induced-Dyskinesias Clinical Features, Incidence, Risk Factors, Management and Impact on Quality of Life. Journal of Parkinson's Disease, 2012, 2, 189-198.	2.8	132
151	Joint hypermobility syndrome: A risk factor for fixed dystonia?. Movement Disorders, 2012, 27, 1070-1070.	3.9	12
152	Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiology of Disease, 2012, 46, 581-589.	4.4	184
153	Validation of the MDSâ€UPDRS Part I for nonmotor symptoms in Parkinson's disease. Movement Disorders, 2012, 27, 79-83.	3.9	97
154	Psychogenic dystonia. , 2012, , 307-319.		0
155	Apathy and depression scales in Parkinson's disease: Are they good enough?. Journal of the Neurological Sciences, 2011, 310, 216-219.	0.6	16
156	The Role of Cognitive-Behavioural Therapy for Patients with Depression in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-8.	1.1	11
157	Adolescent and Adult Children of Parents with Parkinson's Disease: Incorporating Their Needs in Clinical Guidelines. Parkinson's Disease, 2011, 2011, 1-6.	1.1	16
158	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
159	Reply: Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 2011, 26, 191-192.	3.9	0
160	The <i>Movement</i> Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Movement Disorders, 2011, 26, 1985-1992.	3.9	52
161	Healthâ€related qualityâ€ofâ€life scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2371-2380.	3.9	234
162	Wearingâ€off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	3.9	101

#	ARTICLE	IF	CITATIONS
163	Hyperkinetic psychogenic movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 719-729.	1.8	15
164	Parkinson disease clinical subtypes and their implications. Nature Reviews Neurology, 2011, 7, 247-248.	10.1	16
165	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
166	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	3.9	106
167	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Movement Disorders, 2010, 25, 805-822.	3.9	193
168	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 1131-1142.	3.9	90
169	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 2704-2716.	3.9	214
170	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205
171	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Movement Disorders, 2010, 25, 2493-2500.	3.9	405
172	STREPTOCOCCAL INFECTION, TOURETTE SYNDROME, AND OCD: IS THERE A CONNECTION? PANDAS: HORSE OR ZEBRA?. Neurology, 2010, 74, 1397-1399.	1.1	21
173	Hot-Cross Bun Sign. , 2010, , 26.		0
174	Refinement and validation of the Parental Illness Impact Scale. Parkinsonism and Related Disorders, 2010, 16, 181-185.	2.2	12
175	Health-Related Quality of Life in Movement Disorders. , 2010, , 4013-4034.		3
176	Chapter 6 The management of early Parkinson's disease. , 2010, , .		0
177	Comparative responsiveness of Parkinson's disease scales to change over time. Movement Disorders, 2009, 24, 813-818.	3.9	62
178	Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders, 2009, 24, 2175-2186.	3.9	471
179	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Movement Disorders, 2009, 24, 1366-1374.	3.9	138
180	Myoclonus in complex regional pain syndrome. Movement Disorders, 2009, 24, 314-316.	3.9	22

#	ARTICLE	IF	CITATIONS
181	The prognosis of fixed dystonia: A follow-up study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 592-597.	2.2	71
182	Dopamine dysregulation syndrome, impulse control disorders and punning after deep brain stimulation surgery for Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1148-1152.	1.5	220
183	Streptococcal infection, Tourette syndrome, and OCD. <i>Neurology</i> , 2009, 73, 1256-1263.	1.1	94
184	Depression, anxiety and apathy in Parkinson's disease. , 2009, , 107-120.		1
185	Cortical excitability is abnormal in patients with the "fixed dystonia" syndrome. <i>Movement Disorders</i> , 2008, 23, 646-652.	3.9	111
186	Survival in multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 294-296.	3.9	112
187	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	3.9	215
188	Reversible "appliance sign" secondary to diffuse large B cell lymphoma. <i>Movement Disorders</i> , 2008, 23, 2426-2428.	3.9	10
189	Movement Disorder Society's sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
190	Are patients with somatization disorder highly suggestible?. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 232-235.	4.5	8
191	A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. <i>BMC Neurology</i> , 2008, 8, 21.	1.8	80
192	Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2008, 22, 563-586.	5.9	79
193	Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 586-587.	2.2	9
194	The Gilles de la Tourette Syndrome "Quality of Life Scale (GTS-QOL). <i>Neurology</i> , 2008, 71, 1410-1416.	1.1	204
195	Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. <i>Neurology</i> , 2008, 71, 474-480.	1.1	246
196	Quantifying the impact of dyskinesias in PD. <i>Neurology</i> , 2007, 69, 555-563.	1.1	40
197	Estimated life expectancy of Parkinson's patients compared with the UK population. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1304-1309.	1.9	121
198	Testing the validity of the PDQ-39 in patients with MSA. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 152-156.	2.2	5

#	ARTICLE	IF	CITATIONS
199	1.179 A rating instrument for hallucinations in Parkinson's disease: The University of Miami Hallucinations Questionnaire (UMHQ.v2). <i>Parkinsonism and Related Disorders</i> , 2007, 13, S54.	2.2	0
200	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
201	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	3.9	583
202	Rate of clinical progression in Parkinson's disease. A prospective study. <i>Movement Disorders</i> , 2007, 22, 938-945.	3.9	129
203	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. <i>Movement Disorders</i> , 2007, 22, 1757-1763.	3.9	246
204	Measuring health-related quality of life in MSA: The MSA-QoL. <i>Movement Disorders</i> , 2007, 22, 2332-2338.	3.9	49
205	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>European Journal of Neurology</i> , 2007, 14, 66-72.	3.3	37
206	TOURETTE'S SYNDROME, TICS AND OBSESSIVE-COMPULSIVE DISORDERS. , 2007, , 214-221.		0
207	Quality of life and depression in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 151-157.	0.6	320
208	Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 35-41.	2.2	419
209	Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. <i>Lancet Neurology</i> , The, 2006, 5, 355-363.	10.2	324
210	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	3.9	102
211	Minimal clinically important change on the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2006, 21, 1200-1207.	3.9	253
212	Time of loss of employment in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1839-1843.	3.9	61
213	Measuring quality of life in PSP. <i>Neurology</i> , 2006, 67, 39-44.	1.1	61
214	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.	0.2	0
215	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.	3.6	46
216	Entacapone in the treatment of Parkinson's disease. <i>Lancet Neurology</i> , The, 2005, 4, 366-370.	10.2	96

#	ARTICLE	IF	CITATIONS
217	Depressive symptoms and life satisfaction in patients with multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, 951-957.	3.9	98
218	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005, 112, 1677-1686.	2.8	75
219	Dissociation, Childhood Interpersonal Trauma, and Family Functioning in Patients With Somatization Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 899-905.	7.2	158
220	Driving in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 159-159.	1.9	9
221	Measuring health-related quality of life in patients with progressive supranuclear palsy. <i>Neurocase</i> , 2005, 11, 246-249.	0.6	4
222	Reliability of self-reported diagnoses in patients with neurologically unexplained symptoms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 608-611.	1.9	39
223	Psychiatric aspects of Parkinson's disease. <i>Journal of Neurology</i> , 2004, 251, 795-804.	3.6	162
224	Occurrence of atypical parkinsonism in Indians and Caucasians. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 155-156.	2.1	1
225	Patterns of EMG-EMG coherence in limb dystonia. <i>Movement Disorders</i> , 2004, 19, 758-769.	3.9	60
226	The syndrome of fixed dystonia: an evaluation of 103 patients. <i>Brain</i> , 2004, 127, 2360-2372.	7.6	338
227	Development of a measure of the impact of chronic parental illness on adolescent and adult children. The Parental Illness Impact Scale (Parkinson's disease). <i>Parkinsonism and Related Disorders</i> , 2004, 10, 399-405.	2.2	19
228	Impact of Parkinson's disease on patients' adolescent and adult children. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 391-397.	2.2	36
229	Anti-basal ganglia antibodies in patients with atypical dystonia and tics. <i>Neurology</i> , 2004, 63, 156-158.	1.1	36
230	Quality of life in patients with orthostatic tremor. <i>Journal of Neurology</i> , 2003, 250, 212-215.	3.6	35
231	Young- versus older-onset Parkinson's disease: Impact of disease and psychosocial consequences. <i>Movement Disorders</i> , 2003, 18, 1250-1256.	3.9	234
232	Health-related quality of life in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2003, 18, 1464-1469.	3.9	68
233	Sweating dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 1459-1463.	3.9	146
234	Parkin disease: a phenotypic study of a large case series. <i>Brain</i> , 2003, 126, 1279-1292.	7.6	427

#	ARTICLE	IF	CITATIONS
235	How valid is the clinical diagnosis of Parkinson's disease in the community?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 529-534.	1.9	237
236	Novel three-stage ascertainment method. Neurology, 2002, 58, 1820-1825.	1.1	53
237	Quality of life in stiff person syndrome. Movement Disorders, 2002, 17, 1064-1067.	3.9	13
238	How common are complications of Parkinson's disease?. Journal of Neurology, 2002, 249, 419-423.	3.6	135
239	Ropinirole for the treatment of tremor in early Parkinson's disease. European Journal of Neurology, 2002, 9, 253-257.	3.3	43
240	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26
241	What contributes to depression in Parkinson's disease?. Psychological Medicine, 2001, 31, 65-73.	4.5	209
242	Poetic talent unmasked by treatment of Parkinson's disease. Movement Disorders, 2001, 16, 1175-1176.	3.9	69
243	Arm tremor in cervical dystonia differs from essential tremor and can be classified by onset age and spread of symptoms. Brain, 2001, 124, 1765-1776.	7.6	95
244	Firing patterns of pallidal cells in Parkinsonian patients correlate with their pre-pallidotomy clinical scores. NeuroReport, 2000, 11, 3413-3418.	1.2	21
245	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47
246	Benign hereditary chorea?Entity or syndrome?. Movement Disorders, 2000, 15, 280-288.	3.9	80
247	How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Movement Disorders, 2000, 15, 1112-1118.	3.9	438
248	Essential tremor: an overdiagnosed condition?. Journal of Neurology, 2000, 247, 955-959.	3.6	201
249	What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 308-312.	1.9	1,092
250	Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London. BMJ: British Medical Journal, 2000, 321, 21-22.	2.3	211
251	Low-dose olanzapine for levodopa induced dyskinesias. Neurology, 2000, 55, 795-799.	1.1	72
252	Multiple system atrophy/progressive supranuclear palsy: α -Synuclein, synphilin, tau, and <i>APOE</i> .	1.1	82

#	ARTICLE	IF	CITATIONS
253	Differentiation of atypical parkinsonian syndromes with routine MRI. <i>Neurology</i> , 2000, 54, 697-697.	1.1	401
254	Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazarooids in Parkinson's disease. <i>Brain</i> , 2000, 123, 1380-1390.	7.6	266
255	The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 67-73.	1.9	279
256	Relevance of PSP and MSA to clinical practice. <i>Lancet, The</i> , 2000, 355, 754-755.	13.7	2
257	Dyskinesias and motor fluctuations in Parkinson's disease. <i>Brain</i> , 2000, 123, 2297-2305.	7.6	547
258	Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. <i>Brain</i> , 1999, 122, 1121-1132.	7.6	241
259	Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 511-517.	1.9	28
260	Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. <i>Movement Disorders</i> , 1999, 14, 252-255.	3.9	72
261	Atypical and typical cranial dystonia following dental procedures. <i>Movement Disorders</i> , 1999, 14, 492-496.	3.9	103
262	An unusual jaw tremor with characteristics of primary orthostatic tremor. <i>Movement Disorders</i> , 1999, 14, 528-530.	3.9	23
263	The dancing larynx? a variant of palatal tremor?. <i>Movement Disorders</i> , 1999, 14, 882-883.	3.9	6
264	Overdiagnosis of essential tremor. <i>Lancet, The</i> , 1999, 353, 1498-1499.	13.7	24
265	Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. <i>Lancet, The</i> , 1999, 354, 1771-1775.	13.7	573
266	Olivopontocerebellar atrophy and multiple system atrophy: Clinical follow-up of 10 patients studied with PET. <i>Annals of Neurology</i> , 1998, 44, 151-152.	5.3	3
267	Young-onset Parkinson's disease revisited—clinical features, natural history, and mortality. <i>Movement Disorders</i> , 1998, 13, 885-894.	3.9	286
268	Huntington's disease and other choreas. <i>Journal of Neurology</i> , 1998, 245, 709-716.	3.6	87
269	Clinical usefulness of magnetic resonance imaging in multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 65-71.	1.9	236
270	A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. <i>Brain</i> , 1998, 121, 59-75.	7.6	120

#	ARTICLE	IF	CITATIONS
271	The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1998, 21, 169-75.	0.7	27
272	Directional bias of initial visual exploration A symptom of neglect in Parkinson's disease. <i>Brain</i> , 1996, 119, 79-87.	7.6	60
273	Iodine-123-iodo-lisuride SPECT in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 1996, 37, 22-5.	5.0	9
274	Measuring quality of life in multiple system atrophy. , 0, , 60-70.		0